Mersana Therapeutics

Quarterly Financials

Values in thousands 2024-09-30 2024-06-30 2024-03-31 2023-12-31
Revenue
$12,598
$2,293
$9,245
$10,701
Gross Profit
12,598
-14,952
8,822
10,254
EBITDA
-9,695
-22,882
-17,881
-18,049
EBIT
-10,097
-23,285
-18,304
-18,496
Net Income
-11,501
-24,268
-19,306
-19,544
Net Change In Cash
12,598
2,293
9,245
10,701
Free Cash Flow
-8,577
-21,855
-32,788
-34,534
Cash
78,868
58,998
75,186
174,561
Basic Shares
122,721
122,440
121,424
120,614

Annual Financials

Values in thousands 2023-12-31 2022-12-31 2021-12-31 2020-12-31
Revenue
$36,855
$26,581
$43
$828
Gross Profit
-111,414
25,654
-131,970
-66,208
EBITDA
-166,080
-199,957
-167,938
-86,676
EBIT
-167,597
-200,884
-168,793
-87,686
Net Income
-171,670
-207,540
-169,205
-88,404
Net Change In Cash
36,855
26,581
43
828
Cost of Revenue
-76,990
192,743
Free Cash Flow
-171,050
-51,560
-140,636
-75,169
Cash
174,561
280,712
177,947
255,094
Basic Shares
116,112
93,654
70,580
61,485

Earnings Calls

Quarter EPS
2024-09-30
-$0.09
2024-06-30
-$0.20
2024-03-31
-$0.16
2023-12-31
-$0.16